Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials-Reference-Cited by-同舟云学术

Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials

Published:2024-01 Issue:1 Volume:22 Page:16-19
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Francque Sven M.^ORCID,Noureddin Mazen,Krag Aleksander

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): a randomized phase 2b study;Loomba;Clin Gastroenterol Hepatol,2024

2. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study;Abdelmalek;Clin Gastroenterol Hepatol,2024

3. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study;Anstee;Clin Gastroenterol Hepatol,2024

4. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD;Brunt;J Hepatol,2022

5. Topline results from a new analysis of the REGENERATE trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis;Sanyal;Hepatology,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A turning point in hepatology? EASL reflects on the first approved drug for MASH;Journal of Hepatology;2024-08

2. Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo;Scientific Reports;2024-07-23

3. Combination Treatment in MASLD: The Next Frontier;Clinical Gastroenterology and Hepatology;2024-05

4. MASH clinical trials and drugs pipeline: An impending tsunami;Hepatology;2024-03-19